Dana Investment Advisors Inc. Buys 91,787 Shares of DENTSPLY SIRONA Inc. $XRAY

Dana Investment Advisors Inc. lifted its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 32.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 371,741 shares of the medical instruments supplier’s stock after acquiring an additional 91,787 shares during the period. Dana Investment Advisors Inc.’s holdings in DENTSPLY SIRONA were worth $4,249,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. First Eagle Investment Management LLC boosted its position in shares of DENTSPLY SIRONA by 3.2% during the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after purchasing an additional 458,744 shares in the last quarter. Connable Office Inc. bought a new position in shares of DENTSPLY SIRONA in the 4th quarter worth $166,000. State of New Jersey Common Pension Fund D lifted its holdings in shares of DENTSPLY SIRONA by 37.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 210,220 shares of the medical instruments supplier’s stock worth $2,403,000 after purchasing an additional 57,194 shares in the last quarter. Skylands Capital LLC bought a new position in shares of DENTSPLY SIRONA in the 4th quarter worth $1,079,000. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its holdings in shares of DENTSPLY SIRONA by 35.9% in the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 143,977 shares of the medical instruments supplier’s stock worth $1,646,000 after purchasing an additional 38,039 shares in the last quarter. Institutional investors own 95.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on XRAY shares. UBS Group cut their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Zacks Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Citigroup assumed coverage on shares of DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price target on the stock. Robert W. Baird raised their price target on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Finally, Barrington Research raised their price target on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, DENTSPLY SIRONA has an average rating of “Hold” and a consensus target price of $13.82.

Insider Activity at DENTSPLY SIRONA

In other news, Director James D. Forbes bought 5,000 shares of the company’s stock in a transaction on Monday, March 9th. The shares were purchased at an average price of $12.48 per share, with a total value of $62,400.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at $124,800. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gregory T. Lucier bought 27,555 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were purchased at an average cost of $14.24 per share, for a total transaction of $392,383.20. Following the transaction, the director owned 27,555 shares in the company, valued at approximately $392,383.20. This represents a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 70,000 shares of company stock worth $956,437. Insiders own 0.52% of the company’s stock.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $10.07 on Monday. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The stock’s fifty day simple moving average is $11.72 and its two-hundred day simple moving average is $11.90. DENTSPLY SIRONA Inc. has a 1-year low of $9.85 and a 1-year high of $17.09. The stock has a market cap of $2.02 billion, a PE ratio of -3.20, a price-to-earnings-growth ratio of 1.20 and a beta of 0.93.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The firm had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. During the same period in the prior year, the business earned $0.43 EPS. DENTSPLY SIRONA’s quarterly revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, analysts forecast that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.